Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - metformin hydrochloride, dapagliflozin propanedjol monohydrate - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo huwa indikat fl-adulti għall-kura ta 'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju:• f'pazjenti li mhumiex ikkontrollati biżżejjed dwar l-ogħla doża ttollerata ta' metformin waħdu • f'kombinazzjoni ma ' prodotti mediċinali oħra għall-kura tad-dijabete f'pazjenti li mhumiex ikkontrollati biżżejjed b'metformin u dawn il-prodotti mediċinali• fil-pazjenti li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta dapagliflozin u metformin bħala pilloli separati. għall-riżultati tal-istudju fir-rigward tal-kombinazzjoni ta ' terapiji, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati, ara sezzjonijiet 4. 4, 4. 5 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamide - epilessija - anti-epilettiċi, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilettiji, parzjali - anti-epilettiċi, - lacosamide ucb huwa indikat bħala monoterapija u terapija aġġuntiva fil-kura ta 'aċċessjonijiet ta' bidu parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja f'adulti, adolexxenti u tfal minn 4 snin b'epilessija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - trapjant ta 'ċelloli staminali ematopojetiċi - aġenti antineoplastiċi - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influwenza, bniedem - antivirali għal użu sistemiku - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - aġenti antineoplastiċi - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamide - epilessija - anti-epilettiċi, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.